- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07575152
Estimation of Fetal Weight by Measuring Abdominal Circumference, Abdominal Subcutaneous Soft Tissue Thickness, Femur Length and Mid-thigh Soft Tissue Thickness
Estimation of Fetal Weight by Measuring Abdominal Circumference, Abdominal Subcutaneous Soft Tissue Thickness, Femur Length and Mid-thigh Soft Tissue Thickness: Cross Sectional Study.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Accurate estimation of fetal weight (EFW) is fundamental to modern obstetric management. Traditional sonographic biometry-utilizing biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL)-is the standard for predictive modeling. However, these parameters are limited by significant inter- and intra-observer variability and a loss of precision at the extremes of fetal weight, such as in cases of macrosomia or growth restriction. Furthermore, conventional formulas often fail to account for fetal adiposity, which constitutes 10-12% of total neonatal body mass. Recent literature suggests that the integration of soft tissue thickness (STT) measurements-specifically mid-arm, subscapular, abdominal subcutaneous, and mid-thigh thickness-can enhance the accuracy of EFW. While the Scioscia and modified Scioscia formulas rely exclusively on FL and mid-thigh measurements, this study proposes a novel, multi-parametric approach. By combining AC, fetal abdominal subcutaneous tissue thickness, FL, and mid-thigh soft tissue thickness, we hypothesize that our formula offers a non-inferior predictive value. This model accounts for a broader range of biological variants and soft tissue distribution patterns that significantly influence overall fetal mass.
Detailed history (maternal age, obstetric history, medical history, previous macrosomic fetuses, previous shoulder dystocia). Gestational age is calculated from the first day of the last menstrual period and confirmed by either a first- or second-trimester ultrasound scan. When the ultrasound-determined gestational age differed from that calculated from the last menstrual period by >7 days in the first trimester, or by >10 days in the second trimester, the ultrasound-determined gestational age is used.
The study will be bi-phasic, 1st phase is model development phase in which we develop a mathematical model for fetal weight estimation incorporating (abdominal circumference, fetal abdominal subcutaneous soft tissue thickness, femur length, mid-thigh soft tissue thickness), the 2nd phase is a validation and comparison phase in which we test our model and compare it to modified Scioscia formula and conventional Hadlock formula.
For measurement of femur length (FL) Each caliper is placed at the ends of the ossified diaphysis without including the distal femoral epiphysis if it is visible.
For the measurement of AC, the transverse section of the fetal abdomen should be as circular as possible, and the fetal spine preferably in the 3- or 9-o'clock position, umbilical vein at the level of the portal sinus, stomach visible and kidneys not visible. The AC is measured directly at the outer surface of the skin line, with ellipse calipers.
Mid-thigh STT: measured linearly in the standard longitudinal section used for FL measurement. In the middle third of the fetal thigh, with the femur lying parallel to the transducer, mid-thigh STT was measured from the outer margin of the skin to the outer margin of the femur shaft. The measurement was taken, providing that the greater and the lesser trochanter are turned upwards. This section assures the correct view of the lateral side of the femur (vastus lateralis, which is the biggest part of the quadriceps femoris) Abdominal Subcutaneous STT: Measured at the level of the AC plane, anterior 1/3rd of abdominal circumference between outer and inner edges of abdominal wall by ultrasound.
Actual birth weight (AFW) was immediately measured after delivery by a neonatologist using digital medical neonatal scale.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Khaled Mustafa Attyia, Master's degree
- Telefoonnummer: +201005503250
- E-mail: khaled.hussien@med.aun.edu.eg
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Singleton Gestation.
- Gestational Age: Participants must be at a term ≥ 37 weeks
- Timing of Examination: Sonographic EFW must be performed within 48 -72 hours prior to delivery.
- Welling to share in the study.
Exclusion Criteria:
- Fetal Anomalies.
- Amniotic Fluid Disorders: oligohydramnios or polyhydramnios
- Maternal morbid obesity (BMI > 40 kg/m2)
- Maternal medical disorders: as diabetes, hypertension, systemic lupus erythromatosis or others affecting fetal growth
- Fetal Hydrops
- Fetal Malpresentation
- Fetal growth restriction
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Full term pregnant women
full term pregnant women with in 48-72 hours of delivery either cesarean section, spontaneous vaginal delivery or induced vaginal delivery.
|
ultrasound examination of full-term pregnant women with 48-72 hours of delivery measuring Abdominal circumference, fetal abdominal subcutaneous soft tissue thickness, femur length and mid-thigh soft tissue thickness.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
development and validation of novel method for fetal weight estimation
Tijdsspanne: within 48- 72 hours of delivery
|
a novel module for fetal weight estimation depending on abdominal circumference, fetal abdominal subcutaneous soft tissue thickness, femur length, mid-thigh soft tissue thickness.
|
within 48- 72 hours of delivery
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, Werner TJ, Alavi A. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol. 2019 Feb;21(1):1-10. doi: 10.1007/s11307-018-1181-3.
- Deter RL. Individualized growth assessment: evaluation of growth using each fetus as its own control. Semin Perinatol. 2004 Feb;28(1):23-32. doi: 10.1053/j.semperi.2003.10.011.
- Scioscia M, Scioscia F, Vimercati A, Caradonna F, Nardelli C, Pinto LR, Selvaggi LE. Estimation of fetal weight by measurement of fetal thigh soft-tissue thickness in the late third trimester. Ultrasound Obstet Gynecol. 2008 Mar;31(3):314-20. doi: 10.1002/uog.5253.
- Lee W, Deter RL, McNie B, Goncalves LF, Espinoza J, Chaiworapongsa T, Romero R. Individualized growth assessment of fetal soft tissue using fractional thigh volume. Ultrasound Obstet Gynecol. 2004 Dec;24(7):766-74. doi: 10.1002/uog.1779.
- Lee W, Deter RL, McNie B, Goncalves LF, Espinoza J, Chaiworapongsa T, Balasubramaniam M, Romero R. The fetal arm: individualized growth assessment in normal pregnancies. J Ultrasound Med. 2005 Jun;24(6):817-28.
- Larciprete G, Di Pierro G, Barbati G, Deaibess T, Jarvis S, Valensise H, Romanini ME, Gioia S, Arduini D. Could birthweight prediction models be improved by adding fetal subcutaneous tissue thickness? J Obstet Gynaecol Res. 2008 Feb;34(1):18-26. doi: 10.1111/j.1447-0756.2007.00741.x.
- Bernstein IM, Goran MI, Amini SB, Catalano PM. Differential growth of fetal tissues during the second half of pregnancy. Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):28-32. doi: 10.1016/s0002-9378(97)80006-3.
- Galan HL, Rigano S, Radaelli T, Cetin I, Bozzo M, Chyu J, Hobbins JC, Ferrazzi E. Reduction of subcutaneous mass, but not lean mass, in normal fetuses in Denver, Colorado. Am J Obstet Gynecol. 2001 Oct;185(4):839-44. doi: 10.1067/mob.2001.117350.
- Skovron ML, Berkowitz GS, Lapinski RH, Kim JM, Chitkara U. Evaluation of early third-trimester ultrasound screening for intrauterine growth retardation. J Ultrasound Med. 1991 Mar;10(3):153-9. doi: 10.7863/jum.1991.10.3.153.
- Chang TC, Robson SC, Boys RJ, Spencer JA. Prediction of the small for gestational age infant: which ultrasonic measurement is best? Obstet Gynecol. 1992 Dec;80(6):1030-8.
- Kurmanavicius J, Burkhardt T, Wisser J, Huch R. Ultrasonographic fetal weight estimation: accuracy of formulas and accuracy of examiners by birth weight from 500 to 5000 g. J Perinat Med. 2004;32(2):155-61. doi: 10.1515/JPM.2004.028.
- Dudley NJ. A systematic review of the ultrasound estimation of fetal weight. Ultrasound Obstet Gynecol. 2005 Jan;25(1):80-9. doi: 10.1002/uog.1751.
- Rosati P, Exacoustos C, Caruso A, Mancuso S. Ultrasound diagnosis of fetal macrosomia. Ultrasound Obstet Gynecol. 1992 Jan 1;2(1):23-9. doi: 10.1046/j.1469-0705.1992.02010023.x.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Endocriene systeemziekten
- Pathologische processen
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Lichaamsgewicht
- Zwangerschap Complicaties
- Suikerziekte
- Foetale ziekten
- Groeistoornissen
- Diabetes complicaties
- Diabetes, zwangerschap
- Zwangerschap bij diabetici
- Geboortegewicht
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Foetale groeivertraging
- Foetale macrosomie
- Zwangerschap
- Reproductie
- Reproductieve fysiologische fenomenen
- Reproductieve en urinaire fysiologische fenomenen
- Bevalling
Andere studie-ID-nummers
- AssiutFetalWT
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .